申请人:NCARDIA B.V.
公开号:US10613078B2
公开(公告)日:2020-04-07
The current disclosure relates to technology for predicting cardiotoxicity of compounds. In vitro methods using human stem-cell derived cardiomyocytes cultured in specific media are disclosed, as well as kits for use in the method. In the method, the cells are treated with a test compound in combination with a mitochondrial toxicant.
本公开涉及预测化合物心脏毒性的技术。公开了使用在特定培养基中培养的人类干细胞衍生心肌细胞的体外方法,以及用于该方法的试剂盒。在该方法中,细胞将与线粒体毒性物质结合使用一种测试化合物进行处理。